Research progress in neoadjuvant therapy for pancreatic neuroendocrine neoplasms
10.3877/cma.j.issn.2095-3232.2024.04.007
- Author:
Yongzheng Li
- Publication Type:Journal Article
- From:
Chinese Journal of Hepatic Surgery（Electronic Edition）
2024;13(4):481-
- CountryChina
- Language:Chinese
-
Abstract:
Pancreatic neuroendocrine neoplasms (pNENs) is a category of highly heterogeneous tumors. Surgery is the only treatment option that offers the potential to cure pNENs. Neoadjuvant therapy enables patients with locally advanced pNENs or liver metastases to obtain the chance of reoperation. Neoadjuvant therapies for pNENs mainly include chemotherapy, targeted therapy, somatostatin analogues, and peptide receptor-radionuclide therapy, etc. CAPTEM regimen and platinum-based chemotherapy regimen are commonly used in chemotherapy. Somatostatin analogues and peptide receptor-radionuclide therapy are primarily given for individuals with high expression of somatostatin receptor. Targeted therapy is mainly delivered for locally advanced well-differentiated pNENs. These regimens can be adopted alone or combined to enhance clinical efficacy. At present, high-level evidence-based medicine evidence is lacking in the selection of treatment regimens, and systematic evaluation is also lacking in comparison of the clinical efficacy among different protocols.
- Full text:2024121111220369994481-0717.pdf
